Medical-devices company Medtronic‘s (NYSE: MDT) stock was in good health on Tuesday. Following the company’s release of its latest set of quarterly figures, investors traded it up by nearly 5%. That was far more than good enough to top the S&P 500 index’s performance — the bellwether index sank by 0.2% on the day.
For its second quarter of fiscal 2024, Medtronic managed to grow its revenue by more than 5% year over year to $8 billion. Profitability went in the opposite direction, but the decline wasn’t severe. Non-GAAP (adjusted) net income dipped by 3% to just under $1.67 billion, or $1.25 per share.
Nevertheless, both headline figures beat analyst projections. On average, prognosticators tracking the medical-device company’s stock were anticipating $7.93 billion on the top line and $1.18 per share for adjusted net income.
In its earnings release, Medtronic attributed its growth to what it termed “continued broad strength across businesses and geographies benefiting from durable fundamentals.” One standout was the company’s line of diabetes products, which saw revenue growth of nearly 10% during the second quarter of fiscal 2023.
Medtronic strongly signaled confidence in its future with a raise in its guidance. For the entirety of this fiscal year, the company believes its revenue will rise by 4.75% over the fiscal 2023 figure. (It was previously guiding for 4.5%.)
It also boosted its estimate for per-share, adjusted net income. This now stands at $5.13 to $5.19, up from the previous $5.08 to $5.16.
10 stocks we like better than Medtronic
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now… and Medtronic wasn’t one of them! That’s right — they think these 10 stocks are even better buys.
*Stock Advisor returns as of November 20, 2023
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
